Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 26, 2026, details the closing of a private offering of exchangeable senior notes by Jazz Pharmaceuticals Plc (Jazz) and its wholly-owned subsidiary, Jazz Investments I Limited. The transaction closed on August 31, 2026.
Key Financial Metrics and Transaction Details
- Debt Issuance: $1.25 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032.
- Net Proceeds: Approximately $1,226.4 million after discounts, commissions, and estimated offering expenses.
- Share Repurchase: Concurrent repurchase of approximately $225.0 million of ordinary shares.
- Repurchase Price: $249.29 per share (last reported sale price on August 26, 2026).
- Interest Rate: 1.875% per year, payable semi-annually in cash beginning March 15, 2027.
- Maturity Date: September 15, 2032.
- Exchange Price: Initial exchange price of approximately $355.24 per ordinary share (2.8150 shares per $1,000 principal amount).
- Maximum Dilution: Up to 5,014,125 ordinary shares may be issued upon exchange based on the initial maximum exchange rate.
Material Changes and Use of Proceeds
The Company expects to use the net proceeds from the notes offering for general corporate purposes. The concurrent share repurchases were funded with existing cash on hand and were executed as part of the share repurchase program announced in July 2024, reducing the remaining authorized amount under that program. The notes are fully and unconditionally guaranteed by Jazz Pharmaceuticals Plc on a senior unsecured basis.
Outlook, Risks, and Contingencies
- Exchange Conditions: Holders may exchange notes prior to June 15, 2032, only under specific conditions, such as the stock price trading at or above 130% of the exchange price for 20 of 30 trading days in a quarter, or if the note price trades below 98% of the product of the stock price and exchange rate.
- Redemption Rights: The Issuer may redeem notes on or after September 20, 2029, if the stock price meets the 130% threshold. Early redemption is also permitted for tax-related events or if outstanding principal falls below $100 million.
- Fundamental Change: Holders may require repurchase at 100% of principal plus accrued interest if a "fundamental change" occurs.
- Events of Default: Includes failure to pay interest or principal, failure to deliver exchange consideration, bankruptcy, and cross-defaults on indebtedness exceeding $125 million.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the use of proceeds and market conditions, which are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the final net proceeds of $1,226.4 million against actual closing statements.
- Confirm the impact of the $225.0 million share repurchase on the remaining authorization under the July 2024 program.
- Review the full Indenture (Exhibit 4.1) for specific covenants and anti-dilution adjustment provisions.
- Monitor the stock price relative to the $355.24 exchange price to assess the likelihood of early exchange or redemption.
- Check subsequent filings for the listing status of the Notes on the Bermuda Stock Exchange or another recognized exchange by March 15, 2027.